Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247952 | 1.00 | CNR2 (0.31) | CNR2 | |
| SCHEMBL3742324 | 1.00 | CNR2 (0.31) | CNR2 | |
| SCHEMBL31069784 | 1.00 | CNR2 (0.31) | CNR2 | |
| SCHEMBL1130554 | 1.00 | CNR2 (0.31) | CNR2 | |
| SCHEMBL2549969 | 0.90 | ADRA2A (0.32) | — | |
| SCHEMBL10227022 | 0.86 | CNR2 (0.31) | CNR2 | |
| SCHEMBL25860783 | 0.86 | — | — | |
| SCHEMBL17421987 | 0.83 | CNR2 (0.30) | CNR2 | |
| SCHEMBL12172138 | 0.79 | CNR2 (0.32) | CNR2 | |
| SCHEMBL22343067 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331072-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | claimed |
| US-20230303619-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-28 | — | — | US | claimed |
| US-20200079790-A1 | METHODS OF SELECTIVE ARYL- AND HETEROARYL-NITROGEN BOND FORMATION | Janssen Sciences Ireland Unlimited Company (IE) | 2020-03-12 | — | — | US | claimed |
| WO-2018170220-A1 | METHODS OF SELECTIVE ARYL- AND HETEROARYL-NITROGEN BOND FORMATION | JANSSEN SCIENCES IRELAND UC (BE) | 2018-09-20 | — | — | WO | claimed |
| EP-2855419-B1 | NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | claimed |
| EP-1778759-B1 | PHOTOSENSITIVE DIELECTRIC RESIN COMPOSITIONS AND THEIR USES | PROMERUS LLC (US) | 2008-11-12 | — | — | EP | claimed |
| US-6596898-B2 | Making a 2-fluoro-2-chlorocyclopropanecarboxylic acid derivative stereoselectively in high yield by reacting a diazoacetic acid derivative with 1-fluoro-1-chloroethylene using metal catalyst having chiral ligands | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | claimed |
| US-12331072-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-20250188116-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025072614-A2 | PHOTOSENSITIVE COMPOSITION CONTAINING PFAS-FREE POLYCYCLOOLEFINIC POLYMERS AND SEMICONDUCTOR DEVICE MADE THEREOF | PROMERUS, LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025072607-A1 | PHOTOSENSITIVE COMPOSITION CONTAINING PFAS FREE POLYCYCLOOLEFINIC TERPOLYMERS AND SEMICONDUCTOR DEVICE MADE THEREOF | PROMERUS, LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250110403-A1 | PHOTOSENSITIVE COMPOSITION CONTAINING PFAS-FREE POLYCYCLOOLEFINIC POLYMERS AND SEMICONDUCTOR DEVICE MADE THEREOF | PROMERUS, LLC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250110399-A1 | PHOTOSENSITIVE COMPOSITION CONTAINING PFAS-FREE POLYCYCLOOLEFINIC TERPOLYMERS AND SEMICONDUCTOR DEVICE MADE THEREOF | PROMERUS, LLC (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20010051750-A1 | PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0858992-B1 | PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-20010023302-A1 | Process for producing optically active hemiesters | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-20 | — | — | US | disclosed |
| EP-1054867-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999036406-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 1999-07-22 | — | — | WO | disclosed |
| EP-0858992-A1 | PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331072-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | VIP, PEPD, MLN | CNR2 4260/4885 |
| US-20200079790-A1 | METHODS OF SELECTIVE ARYL- AND HETEROARYL-NITROGEN BOND FORMATION | ABL1, CYP2F1, NBAS | CNR2 962/4885 |
| US-20010023302-A1 | Process for producing optically active hemiesters | ALDH1A2, CYP8B1, HCCS | CNR2 2485/4885 |
| US-20230303619-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, PEPD, MLN | CNR2 4260/4885 |
| US-20250188116-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, PEPD, MLN | CNR2 4260/4885 |
| US-20010051750-A1 | PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES | CYP2F1, CYP4F2, CYP4F8 | CNR2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.